Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Atossa Therapeutics Completes Type C Meeting With FDA To Review Strategy For Advancing (Z)-Endoxifen

Author: Benzinga Newsdesk | December 04, 2025 08:07am

Company positioned to pursue expedited regulatory pathways in metastatic, neoadjuvant, and risk-reduction settings

Posted In: ATOS